DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
AIN457 is an investigational drug.
There have been 55 clinical trials for AIN457. The most recent clinical trial was a Phase 3 trial, which was initiated on January 16th 2018.
The most common disease conditions in clinical trials are Arthritis, Psoriasis, and Arthritis, Psoriatic. The leading clinical trial sponsors are Novartis Pharmaceuticals, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), and Novartis.
There are three US patents protecting this investigational drug and five international patents.
Recent Clinical Trials for AIN457
|Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.||Novartis Pharmaceuticals||Phase 3|
|Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis||Novartis Pharmaceuticals||Phase 3|
|A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)||Novartis Pharmaceuticals||Phase 3|
Top disease conditions for AIN457
Top clinical trial sponsors for AIN457
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|AIN457||Get Started Free||Methods of administering IgG1 antibodies and methods of suppressing angiogenesis||University of Kentucky Research Foundation (Lexington, KY)||Get Started Free|
|AIN457||Get Started Free||Substituted pyrimidinone-phenyl-pyrimidinyl compounds||CONFLUENCE LIFE SCIENCES, INC. (St. Louis, MO)||Get Started Free|
|AIN457||Get Started Free||Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients||Corning Incorporated (Corning, NY)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|AIN457||Canada||CA2907548||2033-03-13||Get Started Free|
|AIN457||European Patent Office||EP2968556||2033-03-13||Get Started Free|
|AIN457||World Intellectual Property Organization (WIPO)||WO2014160336||2033-03-13||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|